Stocks · News reference
Guggenheim Maintains Buy Rating on Roivant Sciences
Guggenheim has reaffirmed its 'Buy' rating for Roivant Sciences, reflecting a continued positive outlook from the firm.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Roivant Sciences Insider Sold Shares Worth $12.47 Million
An insider at Roivant Sciences Ltd. sold company shares valued at approximately $12.47 million, according to a recent SEC filing.
Nvidia To $300? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts adjusted targets: RIOT upgraded to Buy; WIX downgraded to Underperform; targets also changed for MNDY, ONTO, ROIV, FERG and NVDA.
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48
Roivant Sciences Q2 2027 Earnings Call Transcript
Roivant Sciences (NASDAQ:ROIV) reported second-quarter financial results on Monday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
Roivant Sciences Reports Second Quarter Fiscal 2026 Financial Results and Business Update
Roivant Sciences announced its financial results for the second quarter ended September 30, 2026, highlighting strong early revenue for LISRAYA and progress across its clinical pipeline.